Coronavirus

Free access to BioWorld coronavirus articles

March 31, 2020

The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are constantly updated:

Vaccines and therapeutics in development

Diagnostics on the market and in development

Clinical trials of biopharma products affected by COVID-19

FDA gives nod to Siemens Healthineers’ Rapidpoint 500e blood gas analyzer

March 31, 2020

By Meg Bryant

No Comments

Erlangen, Germany-based Siemens Healthineers AG has secured U.S. FDA clearance for its Rapidpoint 500e blood gas analyzer. Available in CE mark countries since August 2019, the device is used to monitor respiratory distress in critically ill patients, such as those in acute care due to COVID-19.

European IVD med-techs upping efforts to launch rapid COVID-19 screening tests

March 31, 2020

By Bernard Banga

No Comments

PARIS – Europe has turned into the epicenter of the coronavirus pandemic, seeing more than 50% of the cases observed worldwide. In fact, whereas the COVID-19 pandemic has begun declining in China where it originated, there are 400,000 cases of coronavirus worldwide, including more than 200,000 infected by SARS-CoV-2 in the 55 sovereign states in continental Europe, where they are mourning more than 18,000 deaths.

Citing COVID-19, Second Sight to wind down operations

March 31, 2020

By Liz Hollis

No Comments

It has been predicted that the COVID-19 pandemic would cause business disruption. Now, it has claimed a casualty with Second Sight Medical Products Inc., of Sylmar, Calif., which has been forced to wind down operations, citing the pandemic and the impact it will have on the company’s ability to secure financing. Second Sight, which makes the Argus II retinal prosthesis system, said that effective March 31, 84 of its 108 employees will be laid off.

Regulatory front for March 31, 2020

March 31, 2020

No Comments

The latest global regulatory news, changes and updates affecting medical devices and technologies, including: Becton Dickinson, Biotechnology Innovation Organization, Cme America, Ortho-Clinical Diagnostics.

Regulatory actions for March 31, 2020

March 31, 2020

No Comments

Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Bodysphere, Cytosorbents, Enlightenvue, Qiagen, Siemens Healthineers.

Other news to note for March 31, 2020

March 31, 2020

No Comments

Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: 3M, Airon, Aroa Biosurgery, Battelle, Behold.ai Technologies, Carterra, Cubic, Dräger, Echosens, Evqlv, Ford, GE Healthcare, General Motors, Houston Methodist Hospital, Immunoprecise Antibodies, JR Automation, Luminati, Luminex, Metaphy Health, Navidea Biopharmaceuticals, Neumodx, Northwell Health, NTI Nanotechnology, Ozo Life, Phillips-Medsize, Procept, Sectra, Sense Biodetection, Stagezero Life Sciences, Viral Protection Labs, Virgin Orbit, Wellbeing Software, Worldcare Clinical.

Biopharma equities start to recover as financial markets stabilize

March 31, 2020

By Peter Winter

No Comments

After plunging dramatically at the beginning of the month, biopharmaceutical equities appear to be recovering some of the valuation they originally lost when the financial markets cratered. As the curtain closed on a very turbulent month that most investors will want to forget, the BioWorld Biopharmaceutical index finished up 0.75%, but down about 2% for the year.

AM-Pharma set for phase III with additional $52M round, but faces COVID-19 delays

March 31, 2020

By Nuala Moran

No Comments

LONDON – AM-Pharma BV raised a further $52 million for the phase III trial of its recombinant alkaline phosphatase product, Recap, in treating sepsis-associated acute kidney injury (AKI), but now faces a delay in starting the study, as the COVID-19 crisis takes up more and more clinical resources.

Basis for antibodies, vaccines

Structural studies show similarities and differences in SARS, COVID-19 receptor binding

March 31, 2020

By Nuala Moran

No Comments

LONDON – Two papers published online in Nature following accelerated peer review provide fine detail of how the spike protein on the COVID-19 coronavirus binds to the angiotensin converting enzyme 2 (ACE2) through which it infects its human host.

Coronavirus
RSS

Free access to BioWorld coronavirus articles

FDA gives nod to Siemens Healthineers’ Rapidpoint 500e blood gas analyzer

European IVD med-techs upping efforts to launch rapid COVID-19 screening tests

Citing COVID-19, Second Sight to wind down operations

Regulatory front for March 31, 2020

Regulatory actions for March 31, 2020

Other news to note for March 31, 2020

Biopharma equities start to recover as financial markets stabilize

AM-Pharma set for phase III with additional $52M round, but faces COVID-19 delays

Structural studies show similarities and differences in SARS, COVID-19 receptor binding

Popular Stories

South Korea approves first four COVID-19 test kits under urgent-use license

CHF Solutions looks to bring its tech to help COVID-19 patients

Two South Korean COVID-19 kits look overseas, seek FDA approval

Sihuan starts clinical trial of Ebola drug favipiravir for COVID-19

Mallinckrodt to submit IND to FDA for inhaled nitric oxide to treat COVID-19 respiratory distress

BioWorld Premium

Coronavirus RSS

Popular Stories

BioWorld Premium

Coronavirus
RSS